News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,385 Results
Type
Article (14183)
Company Profile (282)
Press Release (251920)
Section
Business (79497)
Career Advice (153)
Deals (13224)
Drug Delivery (35)
Drug Development (50437)
Employer Resources (31)
FDA (5712)
Job Trends (5127)
News (144372)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21632)
ALS (60)
Alzheimer's disease (824)
Antibody-drug conjugate (ADC) (86)
Approvals (5727)
Artificial intelligence (107)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (39)
Biotechnology (232)
Bladder cancer (43)
Brain cancer (19)
Breast cancer (139)
Cancer (1280)
Cardiovascular disease (100)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (304)
Cervical cancer (7)
Clinical research (40849)
Collaboration (495)
Compensation (218)
Complete response letters (13)
COVID-19 (1034)
CRISPR (36)
C-suite (141)
Cystic fibrosis (76)
Data (1331)
Denatured (11)
Depression (28)
Diabetes (122)
Diagnostics (1291)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (76)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (81)
Earnings (29626)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48091)
Executive appointments (396)
FDA (6324)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (462)
Gene editing (87)
Generative AI (9)
Gene therapy (226)
GLP-1 (353)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6586)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (78)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (55)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (200)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (184)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (114)
MASH (47)
Medical device (2587)
Medtech (2588)
Mergers & acquisitions (6249)
Metabolic disorders (359)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1187)
NextGen: Class of 2025 (2016)
Non-profit (852)
Northern California (1528)
Now hiring (21)
Obesity (184)
Opinion (100)
Ovarian cancer (59)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (104)
Partnered (6)
Patents (109)
Patient recruitment (66)
Peanut (35)
People (25487)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14421)
Phase II (19006)
Phase III (12013)
Pipeline (678)
Podcasts (46)
Policy (35)
Postmarket research (852)
Preclinical (6059)
Press Release (30)
Prostate cancer (52)
Psychedelics (35)
Radiopharmaceuticals (211)
Rare diseases (270)
Real estate (1414)
Recruiting (12)
Regulatory (8548)
Reports (15)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (54)
Series A (91)
Series B (59)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1356)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (11971)
Vaccines (204)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (8)
Last 7 days (359)
Last 30 days (1518)
Last 365 days (19943)
2025 (4559)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13747)
2016 (11840)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (52)
Arkansas (5)
Asia (17208)
Australia (2915)
California (3479)
Canada (1044)
China (319)
Colorado (135)
Connecticut (143)
Delaware (87)
Europe (37009)
Florida (408)
Georgia (106)
Idaho (16)
Illinois (209)
India (8)
Indiana (85)
Iowa (1)
Japan (68)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (441)
Massachusetts (2738)
Michigan (69)
Minnesota (134)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (871)
New Mexico (12)
New York (949)
North Carolina (516)
North Dakota (4)
Northern California (1528)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (663)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1356)
Tennessee (25)
Texas (397)
Utah (48)
Virginia (67)
Washington D.C. (28)
Washington State (316)
Wisconsin (13)
266,385 Results for "nabriva therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Nabriva Therapeutics Provides Corporate Update
Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations.
January 6, 2023
·
7 min read
Business
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
Nabriva Therapeutics plc announced it has pivoted its strategic focus towards commercialization efforts, primarily focused on SIVEXTRO, to extend its cash runway, while exploring strategic options.
November 10, 2022
·
14 min read
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Nabriva Therapeutics plc today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright Global Investment Conference.
May 13, 2022
·
1 min read
Pharm Country
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
Nabriva Therapeutics plc announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022.
September 15, 2022
·
6 min read
Business
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
Nabriva Therapeutics plc today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022.
November 7, 2022
·
3 min read
Drug Development
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Nabriva Therapeutics plc announced positive topline results from their Phase 1 clinical trial that assessed the safety and pharmacokinetics (PK) of oral and intravenous (IV) XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF).
November 28, 2022
·
9 min read
Business
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced its financial results for the three months ended June 30, 2022 and provided a corporate update.
August 3, 2022
·
15 min read
Business
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Nabriva Therapeutics plc announced its financial results for the three months ended March 31, 2022 and provided a corporate update.
May 5, 2022
·
12 min read
Pharm Country
Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
Nabriva Therapeutics plc today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the Jefferies London Healthcare Conference.
November 5, 2021
·
1 min read
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2022
Nabriva Therapeutics plc announced that it has granted a non-statutory stock option to purchase an aggregate of 12,000 ordinary shares of Nabriva Therapeutics as an inducement to a newly hired employee.
March 1, 2022
·
1 min read
1 of 26,639
Next
